Latest filings (excl ownership)
DEF 14A
Definitive proxy
26 Apr 24
EFFECT
Notice of effectiveness
10 Apr 24
424B2
Prospectus for primary offering
9 Apr 24
424B2
Prospectus for primary offering
9 Apr 24
8-K
Entry into a Material Definitive Agreement
9 Apr 24
8-K
ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024
9 Apr 24
S-3
Shelf registration
1 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
8-K
Entry into a Material Definitive Agreement
6 Mar 24
8-K
Entry into a Material Definitive Agreement
27 Feb 24
8-K
ImmuCell Announces Unaudited Financial Results for
27 Feb 24
8-K
ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 2023
8 Jan 24
8-K
Entry into a Material Definitive Agreement
16 Nov 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
ImmuCell Announces Unaudited Financial Results for
13 Nov 23
8-K
ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2023
5 Oct 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
ImmuCell Announces Unaudited Financial Results for
10 Aug 23
8-K
Entry into a Material Definitive Agreement
21 Jul 23
S-8
Registration of securities for employees
13 Jul 23
8-K
ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 2023
11 Jul 23
8-K
ImmuCell Announces Change in Timing of Anticipated FDA Submission
29 Jun 23
8-K
ImmuCell Appoints Bryan K. Gathagan to Board of Directors
21 Jun 23
8-K
ImmuCell Announces Unaudited Financial Results for
11 May 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
PRE 14A
Preliminary proxy
18 Apr 23
8-K
ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2023
5 Apr 23
10-K
2022 FY
Annual report
29 Mar 23
8-K
Departure of Directors or Certain Officers
28 Feb 23
8-K
ImmuCell Announces Unaudited Financial Results for
21 Feb 23
8-K
Departure of Directors or Certain Officers
1 Feb 23
8-K
Results of Operations and Financial Condition
9 Jan 23
8-K
ImmuCell Announces Unaudited Financial Results for
21 Nov 22
10-Q
2022 Q3
Quarterly report
21 Nov 22
8-K
ImmuCell to Announce Unaudited Financial Results for
10 Nov 22
NT 10-Q
Notice of late quarterly filing
10 Nov 22
Latest ownership filings
4
David Scott Tomsche
6 Sep 23
4
Bryan K. Gathagan
30 Aug 23
3
Bryan K. Gathagan
21 Jun 23
4
David Scott Tomsche
15 Mar 23
4
Paul R Wainman
24 Jan 23
4
David Scott Tomsche
24 Jan 23
4
Steven T. Rosgen
24 Jan 23
4
David Cunningham
24 Jan 23
4
Gloria F Basse
24 Jan 23
3
Gloria F Basse
24 Jan 23
4
David Scott Tomsche
12 Sep 22
4
David Scott Tomsche
16 Jun 22
4
David Cunningham
14 Jun 22
4/A
David Scott Tomsche
18 May 22
4
JOSEPH H CRABB
18 May 22
4
David Scott Tomsche
18 May 22
4
JOSEPH H CRABB
14 Mar 22
4
Bobbi Jo Brockmann
9 Feb 22
4
MICHAEL F BRIGHAM
9 Feb 22
4
Elizabeth Luttrell Williams
9 Feb 22
4
Gloria F Basse
25 Jun 21
4
Steven T. Rosgen
21 Jun 21
4
David Cunningham
21 Jun 21
4
David Scott Tomsche
21 Jun 21
4
Paul R Wainman
21 Jun 21
4
JONATHAN E ROTHSCHILD
7 Jun 21
SC 13D/A
PESSIN NORMAN H
16 Apr 21
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
4 Feb 21
SC 13G/A
Wellington Trust Company, National Association Multiple Common Trust Funds Trust, Micro Cap Equity Portfolio
3 Feb 21
SC 13G/A
WELLINGTON TRUST Co N A
3 Feb 21
4
Bobbi Jo Brockmann
11 Dec 20
4
David Cunningham
12 Mar 20
4
David Scott Tomsche
12 Mar 20
4
David Scott Tomsche
2 Mar 20
SC 13G
Immucell Corp /De/
29 Jan 20
SC 13G
Beneficial ownership report
28 Jan 20
4
Elizabeth Luttrell Williams
12 Dec 19
4
Bobbi Jo Brockmann
12 Dec 19
SC 13G
Immucell Corp /De/
8 Apr 19
SC 13D/A
Beneficial ownership report (amended)
1 Apr 19